​Contact: +45 38635600 / tomasz.brudek@regionh.dk

Tomasz Brudek

​​Senior researcher

Ph.D., cand.scient.

Alpha-Synuclein is a presynaptic neuronal protein that is linked genetically and neuropathologically to Parkinson’s disease (PD), Multiple System Atrophy (MSA) and Dementia with Lewy bodies (DLBs). α-Synuclein may contribute to PD and MSA pathogenesis in a number of ways. I have focused my research work on investing the role of different α-synuclein species such as monomers (isoforms, truncated variants), oligomers, fibrils, and α-synuclein post-translational modifications in these two synucleinopathies.

Moreover, a growing body of evidence from clinical studies and preclinical animal models emphasize a role of the immune system in the development of PD and MSA. I am concentrating my research on anti-α-synuclein naturally occurring autoantibodies (NAbs) as therapeutic targets and clinical biomarkers. NAbs make up two-thirds of the human antibody pool and may be involved in many functions such as regulatory and protective actions. NAbs in the central nervous system has been implicated in maintaining homeostasis by removing cell debris and are suggested to prevent inflammation by binding and neutralizing cytokines.
My research focus concentrates not only on synucleinopathies but also other proteinopathies including Alzheimer’s disease (AD) and Amyotrophic Lateral Sclerosis (ALS).​

In near future we plan to expand the molecular studies from tissue specific to cell specific by combining UV-laser microdissection- and quantitative RT-PCR techniques with a suitable PCR assays.

​Publication list